Mechanism of shortened bones in mucopolysaccharidosis VII

Molecular Genetics and Metabolism

Volumn 97, Issue 3, 2009, Pages 202-211

  Metcalf, Jason A ^a   Zhang, Yanming ^a   Hilton, Matthew J ^a,b   Long, Fanxin ^a   Ponder, Katherine P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Dysostosis multiplex; Fibroblast growth factor receptor (FGFR); Glycosaminoglycan (GAG); Growth plate; Mucopolysaccharidosis (MPS); Signal transducer and activator of transcription (STAT)

Indexed keywords

CARDIOTROPHIN 1; CARDIOTROPHIN LIKE CYTOKINE FACTOR 1; CATHEPSIN S; CHONDROITIN 4 SULFATE; CILIARY NEUROTROPHIC FACTOR; COLLAGEN TYPE 10; COLLAGEN TYPE 2; COLLAGENASE 3; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FOCAL ADHESION KINASE 1; GAMMA INTERFERON; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; ONCOSTATIN M; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN RECEPTOR; PROTEIN; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE GROWTH; BONE RADIOGRAPHY; CARTILAGE CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GROWTH PLATE; LONG BONE; LOSS OF FUNCTION MUTATION; MALE; MOUSE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; BONE AND BONES; GENE EXPRESSION REGULATION; GLYCOSAMINOGLYCANS; GROWTH PLATE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; MICE, INBRED C57BL; MUCOPOLYSACCHARIDOSIS VII; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIBIA;

MUS;

EID: 67349168769     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.03.005     Document Type: Article

References (57)

1. Neufeld E.F., and Meunzer J. The mucopolysaccharidoses. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). Metabolic and Molecular Basis of Inherited Disease (2001), McGraw-Hill, New York 3421-3452
2. Pastores G.M., Arn P., Beck M., Clarke J.T.R., Guffon N., Kaplan P., Muenzer J., Norato D.Y.J., Shapiro E., Thomas J., Viskochil D., and Wraith J.E. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol. Genet. Metab. 91 (2007) 37-47
3. Mango R.L., Xu L., Sands M.S., Vogler C., Seiler G., Schwartz T., Haskins M.E., and Ponder K.P. Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol. Genet. Metab. 82 (2004) 4-19
4. Vogler C., Birkenmeier E.H., Sly W.S., Levy B., Pegors C., Kyle J.W., and Beamer W.G. A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice. Am. J. Pathol. 136 (1990) 207-217
5. Birkenmeier E.H., Davisson M.T., Beamer W.G., Ganschow R.E., Vogler C.A., Gwynn B., Lyford K.A., Maltais L.M., and Wawrzyniak C.J. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J. Clin. Invest. 83 (1989) 1258-1266
6. Herati R.S., Knox V.W., O'Donnell P., D'Angelo M., Haskins M.E., and Ponder K.P. Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy. Mol. Genet. Metab. 95 (2008) 142-151
7. Evers M., Saftig P., Schmidt P., Hafner A., McLoghlin D.B., Schmahl W., Hess B., von Figura K., and Peters C. Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI. Proc. Natl. Acad. Sci. USA 93 (1996) 8214-8219
8. Clarke L.A., Russell C.S., Pownall S., Warrington C.L., Borowski A., Dimmick J.E., Toone J., and Jirik F.R. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-l-iduronidase gene. Hum. Mol. Genet. 6 (1997) 503-511
9. Liu Y., Xu L., Hennig A.K., Kovacs A., Fu A., Chung S., Lee D., Wang B., Herati R.S., Ogilvie J.M., Cai S., and Ponder K.P. Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol. Ther. 11 (2005) 35-47
10. Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., and Neufeld E.F. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. USA 100 (2003) 1902-1907
11. Garcia A.R., Pan J., Lamsa J.C., and Muenzer J. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J. Inherit. Metab. Dis. 30 (2007) 924-934
12. Bhaumik M., Mulle V.J., Rozaklis T., Johnson L., Dobrenis K., Bhattacharyya R., Wurzelmann S., Finamore P., Hopwood J.J., Walkley S.U., and Stanley P. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 9 (1999) 1389-1396
13. Li H.H., Yu W.H., Rozengurt N., Zhao H.Z., Lyons K.M., Anagnostaras S., Fanselow M.S., Suzuki K., Vanier M.T., and Neufeld E.F. Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding alpha-N-acetylglucosaminidase. Proc. Natl. Acad. Sci. USA 96 (1999) 14505-14510
14. Tomatsu S., Vogler C., Montaño A.M., Gutierrez M., Oikawa H., Dung V.C., Orii T., Noguchi A., and Sly W.S. Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins. Mol. Genet. Metab. 91 (2007) 251-258
15. Byers A., Caterson B., Hopwood J.J., and Foster B.K. Immunolocation analysis of glycosaminoglycans in the human growth plate. J. Histochem. Cytochem. 40 (1992) 275-282
16. van der Eerden B.C.J., Karperien M., and Wit J.M. Systemic and local regulation of the growth plate. Endocr. Rev. 24 (2003) 782-801
17. Su N., Du X., and Chen L. FGF signaling: its role in bone development and human skeleton diseases. Front. Biosci. 13 (2008) 2842-2865
18. Wilkin D.J., Hecht J.T., and Francomano C.J. Achondroplasia and pseudoachondroplasia. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). Metabolic and Molecular Basis of Inherited Disease (2001), McGraw-Hill, New York 5379-5395
19. Chen L., Adar R., Yang X., Monsonego E.O., Li C., Hauschka P.V., Yayon A., and Deng C. Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J. Clin. Invest. 104 (1999) 1517-1525
20. McDowell L.M., Frazier B.A., Studelska D.R., Gilljum K., Chen J., Liu J., Yu K., Ornitz D.M., and Zhang L. Inhibition or activation of Apert Syndrome FGFR2 (S252W) signaling by specific glycosaminoglycans. J. Biol. Chem. 281 (2006) 6924-6930
21. Giri T.K., and Tollefsen D.M. Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood 107 (2006) 2753-2758
22. Apte S.S., Seldin M.F., Hayashi M., and Olsen B.R. Cloning of the human and mouse type X collagen genes and mapping of the mouse type X collagen gene to chromosome 10. Eur. J. Biochem. 206 (1992) 217-224
23. Kohno K., Martin G.R., and Yamada Y. Isolation and characterization of a cDNA for the amino-terminal portion of the pro-alpha 1(II) chain of cartilage collagen. J. Biol. Chem. 259 (1984) 13668-13673
24. Long F., Zhang X.M., Karp S., Yang Y., and McMahon A.P. Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation. Development 128 (2001) 5099-5108
25. Lee K., Lanske B., Karaplis A.C., Deeds J.D., Kohno H., Nissenson R.A., Kronenberg H.M., and Segre G.V. Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development. Endocrinology 137 (1996) 5109-5118
26. Sahni M., Ambrosetti D., Mansukhani A., Gertner R., Levy D., and Basilico C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13 (1999) 1361-1366
27. Sims N.A., Jenkins B.J., Quinn J.M., Nakamura A., Glatt M., Gillespie M.T., Ernst M., and Martin T.J. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J. Clin. Invest. 113 (2004) 379-389
28. Stephanou A., and Latchman D.S. Opposing actions of STAT-1 and STAT-3. Growth Factors 23 (2005) 177-182
29. Lim C.P., and Cao X. Structure, function, and regulation of STAT proteins. Mol. Biosyst. 2 (2006) 536-550
30. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.L., Polakiewicz R.D., Rush J., and Comb M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007) 1190-1203
31. Boyce B.F., and Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473 (2008) 139-146
32. Alvarez J., Costales L., Serra R., Balbín M., and López J.M. Expression patterns of matrix metalloproteinases and vascular endothelial growth factor during epiphyseal ossification. J. Bone Miner. Res. 20 (2005) 1011-1021
33. Ma X., Tittiger M., Knutsen R.H., Kovacs A., Schaller L., Mecham R.P., and Ponder K.P. Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol. Genet. Metab. 94 (2008) 298-304
34. Larsen L., and Röpke C. Suppressors of cytokine signalling: SOCS. APMIS 110 (2002) 833-844
35. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., Nishimoto N., Kajita T., Taga T., Yoshizaki K., Akira S., and Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature 387 (1997) 924-929
36. Klüppel M., Wight T.N., Chan C., Hinek A., and Wrana J.L. Maintenance of chondroitin sulfation balance by chondroitin-4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. Development 132 (2005) 3989-4003
37. Rani M.R., Leaman D.W., Han Y., Leung S., Croze E., Fish E.N., Wolfman A., and Ransohoff R.M. Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J. Biol. Chem. 274 (1999) 32507-32511
38. Kodama H., Fukuda K., Pan J., Makino S., Baba A., Hori S., and Ogawa S. Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ. Res. 81 (1997) 656-663
39. Ernst M., Oates A., and Dunn A.R. Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. J. Biol. Chem. 271 (1996) 30136-30143
40. Grimaud E., Blanchard F., Charrier C., Gouin F., Redini F., and Heymann D. Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis. Cytokine 20 (2002) 224-230
41. Liu F., Aubin J.E., and Malaval L. Expression of leukemia inhibitory factor (LIF)/interleukin-6 family cytokines and receptors during in vitro osteogenesis: differential regulation by dexamethasone and LIF. Bone 31 (2002) 212-219
42. Sandell L.J., Xing X., Franz C., Davies S., Chang L.W., and Patra D. Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthritis Cartilage 16 (2008) 1560-1571
43. Barton B.E., and Murphy T.F. Constitutive expression of IL-6-LIKE cytokines in normal bone marrow: implications for pathophysiology of myeloma. Cytokine 12 (2000) 1537-1545
44. Heinrich P.C., Behrmann I., Müller-Newen G., Schaper F., and Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334 (1998) 297-314
45. Ware C.B., Horowitz M.C., Renshaw B.R., Hunt J.S., Liggitt D., Koblar S.A., Gliniak B.C., McKenna H.J., Papayannopoulou T., Thoma B., Cheng L., Donovan P.J., Peschon J.J., Bartlett P.F., Willis C.R., Wright B.D., Carpenter M.K., Davison B.L., and Gearing D.P. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 121 (1995) 1283-1299
46. Stewart C.L., Kaspar P., Brunet L.J., Bhatt H., Gadi I., Köntgen F., and Abbondanzo S.J. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359 (1992) 76-79
47. Sims N.A., Jenkins B.J., Nakamura A., Quinn J.M., Li R., Gillespie M.T., Ernst M., Robb L., and Martin T.J. Interleukin-11 receptor signaling is required for normal bone remodeling. J. Bone Miner. Res. 20 (2005) 1093-1102
48. Masu Y., Wolf E., Holtmann B., Sendtner M., Brem G., and Thoenen H. Disruption of the CNTF gene results in motor neuron degeneration. Nature 365 (1993) 27-32
49. Oberle S., Schober A., Meyer V., Holtmann B., Henderson C., Sendtner M., and Unsicker K. Loss of leukemia inhibitory factor receptor beta or cardiotrophin-1 causes similar deficits in preganglionic sympathetic neurons and adrenal medulla. J. Neurosci. 26 (2006) 1823-1832
50. Minehata K., Takeuchi M., Hirabayashi Y., Inoue T., Donovan P.J., Tanaka M., and Miyajima A. Oncostatin M maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow. Int. J. Hematol. 84 (2006) 319-327
51. Tanaka M., Hirabayashi Y., Sekiguchi T., Inoue T., Katsuki M., and Miyajima A. Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 102 (2003) 3154-3162
52. Wakitani S., Hondo E., Phichitraslip T., Stewart C.L., and Kiso Y. Upregulation of Indian hedgehog gene in the uterine epithelium by leukemia inhibitory factor during mouse implantation. J. Reprod. Dev. 54 (2008) 113-116
53. Palmqvist P., Persson E., Conaway H.H., and Lerner U.H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J. Immunol. 169 (2002) 3353-3362
54. Xu D., and Qu C.K. Protein tyrosine phosphatases in the JAK/STAT pathway. Front. Biosci. 13 (2008) 4925-4932
55. Stephanou A., Scarabelli T.M., Brar B.K., Nakanishi Y., Matsumura M., Knight R.A., and Latchman D.S. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. J. Biol. Chem. 276 (2001) 28340-28347
56. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., and Schuchman E.H. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 172 (2008) 112-122
57. Rhee S.H., Jones B.W., Toshchakov V., Vogel S.N., and Fenton M.J. Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J. Biol. Chem. 278 (2003) 22506-22512